Show simple item record

dc.contributor.authorWalldorf, J.A.
dc.contributor.authorKishk, O.A.
dc.contributor.authorCampbell, J.D.
dc.date.accessioned2019-05-17T12:52:59Z
dc.date.available2019-05-17T12:52:59Z
dc.date.issued2018
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85044231754&doi=10.5863%2f1551-6776-23.1.54&partnerID=40&md5=5f3f9340babf57aedb82b770bed02ef4
dc.identifier.urihttp://hdl.handle.net/10713/9024
dc.description.abstractVoriconazole is the recommended agent of choice for treatment of invasive aspergillosis; however, achieving therapeutic serum concentrations while avoiding toxicity, both with intravenous and oral formulations, is challenging in infants. We report the case of an infant with confirmed invasive aspergillosis who developed renal toxicity possibly associated with IV voriconazole. Renal function improved upon withdrawal of the IV agent and switch to the oral formulation. The infant subsequently required large oral weight-based dosing to achieve therapeutic voriconazole serum concentrations. This case illustrates a rare side effect associated with voriconazole as well as the issues surrounding the pharmacokinetic profile of voriconazole in a pediatric patient. Copyright Published by the Pediatric Pharmacy Advocacy Group. All rights reserved.en_US
dc.description.urihttps://dx.doi.org/10.5863/1551-6776-23.1.54en_US
dc.language.isoen_USen_US
dc.publisherPediatric Pharmacy Advocacy Group, Inc.en_US
dc.relation.ispartofJournal of Pediatric Pharmacology and Therapeutics
dc.subjectAdverse effecten_US
dc.subjectAspergillosisen_US
dc.subjectDrug-related side effectsen_US
dc.subjectInfanten_US
dc.subjectTherapeutic drug monitoringen_US
dc.subjectVoriconazoleen_US
dc.titleVoriconazole: Poor oral bioavailability and possible renal toxicity in an infant with invasive aspergillosisen_US
dc.typeArticleen_US
dc.identifier.doi10.5863/1551-6776-23.1.54


This item appears in the following Collection(s)

Show simple item record